Literature DB >> 15338183

[Proposed scoring system for assessment of functional impairment due to visual field defects].

J Weber1, U Schiefer, G Kolling.   

Abstract

INTRODUCTION: The purpose of the study is the development of a scoring system for the assessment of functional impairment due to visual field defects, based on the Esterman grid, but adapted to the existing system in the Federal Republic of Germany.
METHODS: The score areas and the evaluation rules were altered iteratively, until the functional score by the new system matched as much as possible the score obtained from the existing system of geometrical defect patterns.
RESULTS: The visual field is divided into 100 score areas, which are smaller in the visual field center and in its lower region, respectively. The areas inside the reference isopter are counted and taken as total function in percent. Areas with monocular perception are rated with 3/4 points. Functional impairment is defined as the difference of total function to 100%. For 9 of 20 defect patterns, the functional scores are equal. Another six patterns differ by 1-4%. The remaining 5 of 20 patterns differ by 6-8% in either direction.
CONCLUSION: The new system is easier to apply, more consistent, and covers irregular defect patterns. The level of functional impairment is nearly identical with both systems. A transition to the scoring system would considerably increase the certitude and the quality of assessment especially in difficult cases.

Entities:  

Mesh:

Year:  2004        PMID: 15338183     DOI: 10.1007/s00347-004-1073-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  4 in total

1.  Grid for scoring visual fields. II. Perimeter.

Authors:  B Esterman
Journal:  Arch Ophthalmol       Date:  1968-04

2.  Functional scoring of the binocular field.

Authors:  B Esterman
Journal:  Ophthalmology       Date:  1982-11       Impact factor: 12.079

3.  [Assessment of eye damage for private accident insurance].

Authors:  B Gramberg-Danielsen; L Mewe; H Thomann
Journal:  Klin Monbl Augenheilkd       Date:  1982-08       Impact factor: 0.700

4.  Esterman disability rating in severe glaucoma.

Authors:  R P Mills; S M Drance
Journal:  Ophthalmology       Date:  1986-03       Impact factor: 12.079

  4 in total
  7 in total

1.  [Introduction to the topic of functional assessment of sporadic visual field defects].

Authors:  E Zrenner; H Burmeister
Journal:  Ophthalmologe       Date:  2004-10       Impact factor: 1.059

2.  Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.

Authors:  Barbara Wilhelm; Holger Lüdtke; Helmut Wilhelm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-08       Impact factor: 3.117

3.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

Review 4.  [Conventional techniques of visual field examination: part 4 Static perimetry: interpretation--perimetric indices--follow-up--perimetry in childhood].

Authors:  U Schiefer; J Pätzold; B Wabbels; F Dannheim
Journal:  Ophthalmologe       Date:  2006-03       Impact factor: 1.059

5.  [Essential aspects of ophthalmological expert assessment in private accident insurance].

Authors:  F Tost
Journal:  Ophthalmologe       Date:  2014-06       Impact factor: 1.059

Review 6.  [Recommendations for a standardized perimetry within the framework of epilepsy surgery].

Authors:  M T Lutz; T Mayer; U Schiefer
Journal:  Ophthalmologe       Date:  2011-07       Impact factor: 1.059

7.  [Conventional perimetry. Antiquated or indispensable for functional glaucoma diagnostics?].

Authors:  F Tonagel; B Voykov; U Schiefer
Journal:  Ophthalmologe       Date:  2012-04       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.